资源描述：
《《additionofvaricellazostervirus–specifictcellstocytomegalovirus,epstein-barrvirusandadenovirustri-specifictcell》由会员上传分享，免费在线阅读，更多相关内容在行业资料-天天文库。
1、Cytotherapy,2015;17:1406e1420AdditionofvaricellazostervirusespecificTcellstocytomegalovirus,Epstein-Barrvirusandadenovirustri-specificTcellsasadoptiveimmunotherapyinpatientsundergoingallogeneichematopoieticstemcelltransplantation1,21,2,31,2,41,2,4CHUNK.K.MA,EMILYBLYTH,LEIGHTONC
2、LANCY,RENEESIMMS,1,2,41,2,41,2JANEBURGESS,REBECCABROWN,SHIVASHNIDEO,1,2,31,2,3,4KENNETHP.MICKLETHWAITE&DAVIDJ.GOTTLIEB12FacultyofMedicine,UniversityofSydney,Sydney,Australia,WestmeadMillenniumInstitute,CentreforCancer34Research,Sydney,Australia,BloodandMarrowTransplantUnit,De
3、partmentofHaematology,andSydneyCellandGeneTherapyLaboratory,WestmeadHospital,Sydney,AustraliaAbstractBackgroundaims.Virus-specificT-cellimmunotherapyisemergingasapromisingmanagementstrategyforvirusinfectionsinpatientsafterhematopoieticstemcelltransplant(HSCT).Herewepresentoutc
4、omesof10adultpatientswhoreceivedmulti-virus-specificTcellsprophylacticallyafterHSCT.Methods.Donor-derivedcytomegalovirus(CMV)-,Epstein-Barrvirus(EBV)-,adenoviral-andvaricellazostervirus(VZV)-specificTcellsweregeneratedinasinglecultureandadminis-72teredtoHSCTpatientsatadoseof21
5、0/mvirus-specificTcellsatamedianof63dayspost-transplant.Patientsweremonitoredfor12monthsforevidenceofviralreactivationandgraft-versus-hostdisease.Results.Therewasnoacuteinfusion-relatedtoxicity.SixpatientsdevelopedCMVreactivationafterT-cellinfusionwithamedianpeakCMVDNAtiterof6
6、00copiespermilliliter,and1receivedCMV-specificpharmacotherapypost-infusion.NoEBV,adenoviralorVZVreactivationordiseasewasreported.Usinginterferon-gElispotanalysisonpost-infusionsamples,weidentifiedanti-viralimmunityagainstallvirusesincludingVZV.Threepatients(30%)developedgradeII
7、eIVacutegraft-versus-hostdisease.Conclusions.Thisisthefirstdescriptionoftheuseofamulti-virus-specificT-cellproductcontainingcellsspecificforVZVafterallogeneicHSCT.TheT-cellproductappearssafeinthesettingofHSCTandconfirmsourpreviousfindingsregardingCMVcontrolandtreatment.Alargerstud
8、ywithlongerfollow-upisrequiredtodeterminetheefficacyofVZV-specificTcel
